7 hours Apellis Dives As Worse-Than-Expected Syfovre Sales Add Fuel To Market WoesInvestor's Business Daily
Apellis stock plunged Tuesday after third-quarter sales of the company’s eye drug, Syfovre, widely missed Wall Street’s expectations.
The post Apellis Dives As Worse-Than-Expected Syfovre Sales Add Fuel To Market Woes appeared first on Investor's …